Perspective Therapeutics

Perspective Therapeutics FCF per Share

The Free Cash Flow per Share of Perspective Therapeutics (CATX) as of Oct 27, 2026 is -1.29 USD. In the previous year, Free Cash Flow per Share was -1.03 USD — a change of 25.33% (lower).

FCF per Share

-1.29USD

YoY

25.33%

Last updated:

Free Cash Flow per Share of Perspective Therapeutics is 2025 -1.29 USD. Free Cash Flow per Share of Perspective Therapeutics was 2024 -1.03 USD. It decreases by 25.33% lower compared to the previous year.

The Perspective Therapeutics FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
-0.11 USD
Jan 1, 2019
-0.08 USD
Jan 1, 2020
-0.06 USD
Jan 1, 2021
-0.06 USD
Jan 1, 2022
-0.15 USD
Jan 1, 2023
-0.23 USD
Jan 1, 2024
-1.03 USD
Jan 1, 2025
-1.29 USD
The Perspective Therapeutics FCF per Share history
YEARFCF per ShareYoY
-1.29USD+25.33%
-1.03USD+353.12%
-0.23USD+56.39%
-0.15USD+147.86%
-0.06USD+1.94%
-0.06USD-29.50%
-0.08USD-25.23%
-0.11USD-4.16%
-0.11USD+43.08%
-0.08USD+18.88%
-0.07USD+12.46%
-0.06USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Perspective Therapeutics Stock analysis

What does Perspective Therapeutics do? Perspective Therapeutics Inc is a biotechnology company based in Seattle, United States, specializing in radiopharmaceutical development. The firm employs 163 people and focuses on advanced cancer treatments using proprietary technology that leverages the alpha-emitting isotope 212Pb. This approach delivers targeted radiation to cancer cells via specialized peptides, aiming to maximize efficacy while minimizing toxicity. Additionally, the company develops imaging diagnostics to personalize patient care. Its pipeline includes programs for metastatic melanoma and neuroendocrine tumors, which have entered Phase I/IIa clinical trials at academic institutions. Perspective Therapeutics also produces a 212Pb generator to secure essential isotopes for its clinical activities. The company has been listed on the market since May 31, 2002. Perspective Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Perspective Therapeutics stock

Free Cash Flow per Share of Perspective Therapeutics is -1.29 USD in 2025.

Free Cash Flow per Share of Perspective Therapeutics changed from -1.03 USD to -1.29 USD, representing a 25.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Perspective Therapeutics since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Perspective Therapeutics

All Key Metrics — Perspective Therapeutics